Identification and characterization of a novel Sso7d scaffold-based binder against Notch1
暂无分享,去创建一个
[1] Brian R. McNaughton,et al. Minimalist Antibodies and Mimetics: An Update and Recent Applications , 2016, Chembiochem : a European journal of chemical biology.
[2] Raja R Srinivas,et al. Strong Enrichment of Aromatic Residues in Binding Sites from a Charge-neutralized Hyperthermostable Sso7d Scaffold Library* , 2016, The Journal of Biological Chemistry.
[3] S. Bray. Notch signalling in context , 2016, Nature Reviews Molecular Cell Biology.
[4] Kevin B Carlin. Engineering Multivalent Protein Affinity Ligands using the Sso7d Scaffold. , 2016 .
[5] D. Scott,et al. Small molecules, big targets: drug discovery faces the protein–protein interaction challenge , 2016, Nature Reviews Drug Discovery.
[6] M. Schmitt,et al. Phage display selection of tight specific binding variants from a hyperthermostable Sso7d scaffold protein library , 2016, The FEBS journal.
[7] M. Kitagawa. Notch signalling in the nucleus: roles of Mastermind-like (MAML) transcriptional coactivators. , 2015, Journal of biochemistry.
[8] K. Garcia,et al. Abstract B068: Structural basis for Notch1 engagement of Delta-like 4 and Jagged1 , 2016 .
[9] I. Weissman,et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging , 2015, Proceedings of the National Academy of Sciences.
[10] Tri Giang Phan,et al. Challenges and opportunities for non-antibody scaffold drugs. , 2015, Drug discovery today.
[11] Richard Nicoletti,et al. 23814, an Inhibitory Antibody of Ligand-Mediated Notch1 Activation, Modulates Angiogenesis and Inhibits Tumor Growth without Gastrointestinal Toxicity , 2015, Molecular Cancer Therapeutics.
[12] M. Fischer,et al. Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency , 2015, Clinical Cancer Research.
[13] K. Garcia,et al. Structural basis for Notch1 engagement of Delta-like 4 , 2015, Science.
[14] S. Jacobs,et al. Selection of high-affinity Centyrin FN3 domains from a simple library diversified at a combination of strand and loop positions. , 2014, Protein engineering, design & selection : PEDS.
[15] S. Gambhir,et al. A Novel Engineered Anti-CD20 Tracer Enables Early Time PET Imaging in a Humanized Transgenic Mouse Model of B-cell Non-Hodgkins Lymphoma , 2013, Clinical Cancer Research.
[16] Scott Banta,et al. Replacing antibodies: engineering new binding proteins. , 2013, Annual review of biomedical engineering.
[17] J. Aster,et al. Intrinsic Selectivity of Notch 1 for Delta-like 4 Over Delta-like 1* , 2013, The Journal of Biological Chemistry.
[18] Nimish Gera,et al. Protein selection using yeast surface display. , 2013, Methods.
[19] N. Perrimon,et al. PAPTi: A Peptide Aptamer Interference Toolkit for Perturbation of Protein-Protein Interaction Networks , 2013, Scientific Reports.
[20] A. Rangarajan,et al. Antibodies against the extracellular domain of human Notch1 receptor reveal the critical role of epidermal-growth-factor-like repeats 25-26 in ligand binding and receptor activation. , 2013, The Biochemical journal.
[21] Hao Wang,et al. A Mutation in EGF Repeat-8 of Notch Discriminates Between Serrate/Jagged and Delta Family Ligands , 2012, Science.
[22] J. Elborn,et al. Anti-inflammatory effects of DX-890, a human neutrophil elastase inhibitor. , 2012, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[23] Y. Miki,et al. Reduction of NOTCH1 expression pertains to maturation abnormalities of keratinocytes in squamous neoplasms , 2012, Laboratory Investigation.
[24] A. Rangarajan,et al. A Monoclonal Antibody against Human Notch1 Ligand–Binding Domain Depletes Subpopulation of Putative Breast Cancer Stem–like Cells , 2011, Molecular Cancer Therapeutics.
[25] R. C. Wright,et al. Highly stable binding proteins derived from the hyperthermophilic Sso7d scaffold. , 2011, Journal of molecular biology.
[26] V. Tolmachev,et al. Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. , 2011, International journal of oncology.
[27] S. Ivy,et al. Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways , 2011, Nature Reviews Clinical Oncology.
[28] Louis M. Weiner,et al. Monoclonal antibodies: versatile platforms for cancer immunotherapy , 2010, Nature Reviews Immunology.
[29] Joachim Feldwisch,et al. Design of an optimized scaffold for affibody molecules. , 2010, Journal of molecular biology.
[30] Deepa Subramanyam,et al. Cooperation of Notch and Ras/MAPK signaling pathways in human breast carcinogenesis , 2009, Molecular Cancer.
[31] M. Vidal,et al. Edgetic perturbation of a C. elegans BCL2 ortholog , 2009, Nature Methods.
[32] Raphael Kopan,et al. The Canonical Notch Signaling Pathway: Unfolding the Activation Mechanism , 2009, Cell.
[33] H. Binz,et al. DARPins: a new generation of protein therapeutics. , 2008, Drug discovery today.
[34] P. Handford,et al. A conserved face of the Jagged/Serrate DSL domain is involved in Notch trans-activation and cis-inhibition , 2008, Nature Structural &Molecular Biology.
[35] P. Alzari,et al. Remodeling a DNA-binding protein as a specific in vivo inhibitor of bacterial secretin PulD , 2007, Proceedings of the National Academy of Sciences.
[36] Eleni Bazigou,et al. Cell signaling and cancer , 2007, Genome Biology.
[37] A. Plückthun,et al. Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.
[38] K. Sakamoto,et al. Distinct roles of EGF repeats for the Notch signaling system. , 2005, Experimental cell research.
[39] A. McMichael,et al. Structural and functional properties of the human notch-1 ligand binding region. , 2004, Structure.
[40] P. B. Vander Horn,et al. A novel strategy to engineer DNA polymerases for enhanced processivity and improved performance in vitro. , 2004, Nucleic acids research.
[41] J. Aster,et al. Notch Signaling in Cancer , 2002, Cancer biology & therapy.
[42] Y. Yazaki,et al. Mouse Jagged1 Physically Interacts with Notch2 and Other Notch Receptors , 1999, The Journal of Biological Chemistry.
[43] J. Boulter,et al. Jagged: A mammalian ligand that activates notch1 , 1995, Cell.
[44] S. Knapp,et al. Solution structure and DNA-binding properties of a thermostable protein from the archaeon Sulfolobus solfataricus , 1994, Nature Structural Biology.